JDRF announces new Chief Scientific Officer, Dr. Sarah Linklater


Toronto, ON (March 21, 2019) – JDRF Canada is pleased to announce the appointment of Dr. Sarah Linklater as Chief Scientific Officer (CSO). Sarah has over a decade of extensive experience as a professional scientific editor, with a focus on clinical diabetes and endocrinology, basic immunology and other areas of the life sciences. Prior to working in publishing, Sarah carried out research on mechanisms of immune regulation at UBC in Vancouver and at the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. In her role as JDRF Canada’s CSO, Sarah will lead the organization’s efforts to advance and expand its research partnerships and support its efforts to effectively engage the type 1 diabetes (T1D) community. Sarah will start her new role on April 16, 2019.

“I’m really excited for the opportunity to shape T1D research in Canada, and work with a global organization whose mission is to improve the lives of people living with T1D and ultimately cure this disease,” said Sarah.

“We are thrilled to have Sarah join our passionate team of professionals.  She brings a unique combination of scientific experience and communications expertise that will help us accelerate our research program,” said Dave Prowten, President and CEO of JDRF Canada. 

Dr. Sarah E. Linklater (née Allan) completed her PhD in Experimental Medicine at the UBC Faculty of Medicine under the supervision of Professor Megan Levings, a JDRF funded researcher. Her PhD studies focused on the function of regulatory T cells in health and autoimmune disease and she has published several peer-reviewed original research articles, reviews and book chapters on the topic, as well as conducted a number of podium presentations. In her latest role, she helped to launch The Lancet Diabetes & Endocrinology, now the leading clinical diabetes journal worldwide, and became Editor-in-Chief in 2017. Her responsibilities included: maintaining an international network of advisors, authors, and peer reviewers; critically appraising and triaging research, review, and opinion content submitted to the journal; overseeing the peer review processes of the editorial team; and leading a variety of special projects in clinical diabetes and endocrinology. 



About JDRF
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is the largest charitable supporter of T1D research. The goal of JDRF is to improve the lives of every person affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.

Since its founding in 1970, JDRF has awarded more than $1.7 billion to T1D research. Past JDRF research efforts have helped to significantly improve the care of people with this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered. 

For more information, please visit jdrf.ca.

Media contact:

Soledad Vega
Manager, Marketing and Communications
JDRF Canada










Stay connected on the latest